Trial Profile

A real world observational study of XERMELO® (telotristat ethyl)

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 02 Mar 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Telotristat etiprate (Primary)
Indications Malignant carcinoid syndrome; Neuroendocrine tumours; Pancreatic cancer
Focus Therapeutic Use
Acronyms TELEACE

Most Recent Events

17 Jan 2021 Results (n=52) evaluating tumor burden in a subgroup of patients with pNETS from the real-world TELEACE study before and after initiating telotristat ethyl (TE) in US clinical practice presented at the 2021 Gastrointestinal Cancers Symposium
25 Jan 2020 Results presented at the 2020 Gastrointestinal Cancers Symposium
24 Jan 2020 According to an Lexicon Pharmaceuticals media release, data from this study were presented at the American Society for Clinical Oncology (ASCO) 2020 Symposium.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com